Bicara Therapeutics (NASDAQ:BCAX) CFO Ivan Hyep Sells 18,244 Shares

Key Points

• Bicara Therapeutics CFO Ivan Hyep sold 18,244 shares at an average price of $18.22, totaling approximately $332,405, reducing his stake by 11.15%.
• Shares of Bicara Therapeutics are currently valued at $18.00, reflecting a 0.9% decrease in stock price, with a market cap of approximately $982.98 million.
• Investment analyses show that Bicara Therapeutics has a consensus rating of "Moderate Buy" with an average target price of $31.86 from various analysts.

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CFO Ivan Hyep sold 18,244 shares of the stock in a transaction that occurred on Tuesday, October 7th. The stock was sold at an average price of $18.22, for a total transaction of $332,405.68. Following the completion of the transaction, the chief financial officer owned 145,355 shares in the company, valued at approximately $2,648,368.10. This trade represents a 11.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Ivan Hyep also recently made the following trade(s):

• On Wednesday, October 8th, Ivan Hyep sold 5,627 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.21, for a total transaction of $102,467.67.
• On Monday, October 6th, Ivan Hyep sold 6,514 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.17, for a total transaction of $118,359.38.

Bicara Therapeutics Stock Down 0.9%

Shares of NASDAQ BCAX traded down $0.17 during midday trading on Wednesday, reaching $18.00. 514,631 shares of the stock were exchanged, compared to its average volume of 579,256. The firm has a 50-day simple moving average of $12.09 and a two-hundred day simple moving average of $11.76. Bicara Therapeutics Inc. has a twelve month low of $7.80 and a twelve month high of $28.09. The firm has a market cap of $982.98 million and a price-to-earnings ratio of -5.68.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.04. Research analysts expect that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BCAX has been the topic of a number of research reports. Wedbush restated an "outperform" rating and issued a $30.00 price objective on shares of Bicara Therapeutics in a report on Tuesday, August 12th. Piper Sandler initiated coverage on Bicara Therapeutics in a report on Monday, August 18th. They issued an "overweight" rating and a $36.00 price objective on the stock. Weiss Ratings reiterated a "sell (e+)" rating on shares of Bicara Therapeutics in a report on Saturday, September 27th. Finally, HC Wainwright reduced their price target on Bicara Therapeutics from $41.00 to $40.00 and set a "buy" rating on the stock in a report on Friday, August 22nd. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Bicara Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $31.86.

Hedge Funds Weigh In On Bicara Therapeutics

Several hedge funds have recently added to or reduced their stakes in BCAX. Vestal Point Capital LP increased its stake in Bicara Therapeutics by 80.6% in the second quarter. Vestal Point Capital LP now owns 5,000,000 shares of the company's stock valued at $46,450,000 after purchasing an additional 2,231,025 shares during the last quarter. Wellington Management Group LLP increased its stake in Bicara Therapeutics by 84.0% in the first quarter. Wellington Management Group LLP now owns 1,394,676 shares of the company's stock valued at $18,173,000 after purchasing an additional 636,708 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of Bicara Therapeutics by 2,351.0% in the second quarter. Bank of America Corp DE now owns 451,228 shares of the company's stock valued at $4,192,000 after acquiring an additional 432,818 shares during the period. Artisan Partners Limited Partnership acquired a new stake in shares of Bicara Therapeutics in the second quarter valued at approximately $3,742,000. Finally, Schroder Investment Management Group boosted its holdings in shares of Bicara Therapeutics by 921.0% in the second quarter. Schroder Investment Management Group now owns 425,341 shares of the company's stock valued at $3,951,000 after acquiring an additional 383,681 shares during the period.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.